MedPath

Moxifloxacin

Generic Name
Moxifloxacin
Brand Names
Avelox, Moxeza, Vigamox
Drug Type
Small Molecule
Chemical Formula
C21H24FN3O4
CAS Number
151096-09-2
Unique Ingredient Identifier
U188XYD42P
Background

Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.

Indication

For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).

Associated Conditions
Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
Clinical Trials
Related News

Antibiotic Resistance In Eye Surgeries

Phase 4
Completed
Conditions
Ocular Surface Microbiome
Antibiotic Resistance
Gut Resistome
Interventions
First Posted Date
2021-02-11
Last Posted Date
2025-03-28
Lead Sponsor
University of California, San Francisco
Target Recruit Count
108
Registration Number
NCT04750655
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

EFFECTS OF MOXIFLOXACIN AND GEMIFLOXACIN ON BLOOD GLUCOSE AND ECG MORPHOLOGY OF EUGLYCEMICS:A CLINICAL STUDY

Phase 1
Completed
Conditions
Blood Glucose, Low
Hypoglycemia
Interventions
First Posted Date
2021-01-05
Last Posted Date
2023-04-12
Lead Sponsor
Shaheed Benazir Bhutto University Sheringal Dir Upper
Target Recruit Count
25
Registration Number
NCT04692623
Locations
🇵🇰

Khyber Medical University,Peshawar, Peshawar, Khyber Pukhtan Khawa, Pakistan

Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects

Phase 1
Completed
Conditions
Symptomatic Neurogenic Orthostatic Hypertension
nOH
Interventions
First Posted Date
2020-12-30
Last Posted Date
2021-04-20
Lead Sponsor
Theravance Biopharma
Target Recruit Count
72
Registration Number
NCT04688632
Locations
🇺🇸

Theravance Biopharma Investigational Site, Tempe, Arizona, United States

A Study of the Cardiac Effects of ALXN2050 in Healthy Adults

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: ALXN2050-matching Placebo
Drug: Moxifloxacin-matching Placebo
First Posted Date
2020-12-09
Last Posted Date
2021-12-29
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
39
Registration Number
NCT04660890
Locations
🇺🇸

Clinical Trial Site, Tempe, Arizona, United States

Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin

Phase 1
Completed
Conditions
HIV Infections
Interventions
Drug: Placebo
First Posted Date
2020-09-25
Last Posted Date
2023-12-06
Lead Sponsor
ViiV Healthcare
Target Recruit Count
50
Registration Number
NCT04563845
Locations
🇺🇸

GSK Investigational Site, Austin, Texas, United States

A Study of the Cardiac Effects of ALXN1840 in Healthy Adults

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2020-09-23
Last Posted Date
2023-08-14
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
57
Registration Number
NCT04560816
Locations
🇺🇸

PPD Development, LP, Austin, Texas, United States

Study to Gather Information on the Influence of BAY1817080 on the Electrical Activity of the Heart Recorded by an Electrocardiogram in Healthy Male and Female Participants

Phase 1
Completed
Conditions
Endometriosis
Overactive Bladder
Cough
Interventions
Drug: Placebo
First Posted Date
2020-06-09
Last Posted Date
2022-01-24
Lead Sponsor
Bayer
Target Recruit Count
42
Registration Number
NCT04423744
Locations
🇩🇪

CRS Clinical Research Services Mannheim GmbH, Mannheim, Baden-Württemberg, Germany

Postoperative Safety Outcomes of Intraoperative Intracameral Preservative-Free Moxifloxacin Versus Levofloxacin

Phase 4
Completed
Conditions
Cataract Senile
Endophthalmitis
Safety Issues
Antibiotic Side Effect
Interventions
First Posted Date
2020-05-27
Last Posted Date
2020-05-27
Lead Sponsor
Peregrine Eye and Laser Institute
Target Recruit Count
114
Registration Number
NCT04403334
Locations
🇵🇭

Peregrine Eye and Laser Instittute, Makati City, MM, Philippines

A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.

Phase 1
Completed
Conditions
Schizophrenia
Interventions
Drug: SEP363856 150 mg
Drug: Placebo
First Posted Date
2020-04-30
Last Posted Date
2024-06-26
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
150
Registration Number
NCT04369391
Locations
🇺🇸

Collaborative Neuroscience Research, LLC, Long Beach, California, United States

🇺🇸

Woodland International Research Group, Little Rock, Arkansas, United States

🇺🇸

Hassman Research Institute, Marlton, New Jersey, United States

and more 4 locations

A Through QT/QTc Study of KW-6356

Phase 1
Completed
Conditions
Parkinson's Disease
Interventions
Drug: Placebo
First Posted Date
2020-04-13
Last Posted Date
2020-09-18
Lead Sponsor
Kyowa Kirin Co., Ltd.
Target Recruit Count
128
Registration Number
NCT04342273
Locations
🇯🇵

Medical Co. LTA Sumida Hospital, Sumida-ku, Tokyo, Japan

🇯🇵

Medical Co. LTA Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy